Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems
Koleva-Kolarova R., Vellekoop H., Huygens S., Versteegh M., Mölken MR-V., Szilberhorn L., Zelei T., Nagy B., Wordsworth S., Tsiachristas A.
The cost–effectiveness and budget impact of introducing extended DPYD testing prior to fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The Netherlands and Hungary were examined. DPYD testing with ToxNav© was cost-effective in all three countries. In the UK and The Netherlands, the ToxNav strategy led to more quality-adjusted life years and fewer costs to the health systems compared with no genetic testing and standard dosing of capecitabine/5-fluorouracil. In Hungary, the ToxNav strategy produced more quality-adjusted life years at a higher cost compared with no testing and standard dose. The ToxNav strategy was found to offer budget savings in the UK and in The Netherlands, while in Hungary it resulted in additional budget costs.